3-(chloromethyl)-N-phenylbenzamide | 351325-32-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(chloromethyl)-N-phenylbenzamide
• CAS: 351325-32-1
• 化学式: C₁₄H₁₂ClNO
• 分子量: 245.708
• InChiKey: NNYXVNDGOOLSLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(chloromethyl)-N-phenylbenzamide 在 silver nitrate 作用下， 以 乙腈 为溶剂， 反应 4.0h， 以38.4%的产率得到3-(phenylcarbamoyl)benzyl nitrate
  参考文献：
  名称：

  New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group

  摘要：

  We have designed cancer antiproliferative compounds, starting from aniline or phenol derivative, which comprise one or two nitrooxymethylphenyl groups as do the hybrid drugs NCX4040 and NCX530. Compound 2a with p-nitrooxymethylbenzoyl-oxy and -amino groups as well as 8a with a p-nitrooxymethylbenzoylamino group showed more promising effects than NCX4040 against human colon and breast cancer cells. Since 2a and 8a, but not NCX4040, arrested human colon carcinoma HCT116 cells in the M phase, the former two compounds may inhibit cell growth differently from NCX4040. Merged images of immunofluorescence-stained a-tubulin and Hoechst-stained nuclei in human fibrosarcoma HT1080 cells showed that 2a and 8a disrupted microtubule formation just as did vincristine, the tubulin polymerization inhibitor. In experiments in vivo, the intraperitoneal administration of 8a at 80 mg/kg/day reduced the growth of HCT116 xenografts in nude mice to T/C 55%. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.05.031
• 作为产物：
  描述：

  3-(氯甲基)苯甲酰氯 、 苯胺 在 sodium carbonate 作用下， 以 水 为溶剂， 生成 3-(chloromethyl)-N-phenylbenzamide
  参考文献：
  名称：

  带有 N-(芳基)-3-取代-苯甲酰胺的 4-苯基哌嗪作为吉祥酪氨酸酶抑制剂的合成、动力学和计算探索

  摘要：

  在目标研究中，合成了一系列新的N- (芳基)-3-[(4-苯基-1-哌嗪基)甲基]苯甲酰胺，其被设想作为酪氨酸酶抑制剂。这些新设计的分子的结构通过IR、 1H -NMR、 13C -NMR、EI-MS和CHN分析数据进行了验证。这些分子针对酪氨酸酶进行了筛选，并探索了它们的抑制活性，与标准相比，这些 3-取代-苯甲酰胺表现出良好至优异的潜力。通过 Lineweaver-Burk 图研究了动力学机制，该图描绘了分子以竞争模式抑制这种酶。此外，还进行了分子对接以确定所有合成分子（配体）与酪氨酸酶活性位点的结合相互作用，结果表明大多数配体表现出有效的结合能值。因此，预计这些分子可能作为治疗酪氨酸酶相关皮肤病的良好治疗支架。

  DOI：

  10.1002/cbdv.202400133

文献信息

• Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
  申请人：——

  公开号：US20020103203A1

  公开（公告）日：2002-08-01

  Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  描述了调节和/或抑制特定蛋白激酶活性的酰胺化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号传导，以调节和/或抑制不需要的细胞增殖。该发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
• [EN] SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE<br/>[FR] AGENTS DE DÉGRADATION À PETITES MOLÉCULES D'HÉLIOS ET PROCÉDÉS D'UTILISATION
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2021087093A1

  公开（公告）日：2021-05-06

  Disclosed are compounds and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof that may cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds to treat diseases and disorders associated with Helios and which may benefit from Helios degradation.

  本文披露了一些化合物及其药用可接受的盐、水合物、溶剂合物、前药、立体异构体或互变异构体，这些化合物可能导致各种蛋白质（例如IKZF2（Helios））的降解。还披露了含有该化合物的药物组合物，以及制备和使用这些化合物治疗与Helios相关的疾病和障碍的方法，这些疾病和障碍可能受益于Helios的降解。
• Chemokine receptor binding heterocyclic compounds
  申请人：——

  公开号：US20020147192A1

  公开（公告）日：2002-10-10

  Tertiary amines containing a multiplicity of heteroaromatic substituents are useful as chemokine receptor modulators.

  含有多种杂环取代基的三级胺可用作化学受体调节剂。
• CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS
  申请人：Bridger Gary

  公开号：US20080090846A1

  公开（公告）日：2008-04-17

  Tertiary amines containing a multiplicity of heteroaromatic substituents are useful as chemokine receptor modulators.

  含有多种杂环芳基取代基的三级胺可用作趋化因子受体调节剂。
• AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：EP1252146A1

  公开（公告）日：2002-10-30